Alaunos Therapeutics Inc Dossier - Source-backed chat

Alaunos Therapeutics Inc

TCRTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.31

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.89Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.3M

Enterprise Value $2.1M

Shares Outstanding 2.7M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Alaunos Therapeutics, Inc. (TCRT) is in a highly precarious financial position, transitioning from a clinical-stage oncology cell therapy developer to an early-stage preclinical obesity drug developer. Following the wind-down of its TCR-T Library Phase 1/2 trial, the company's sole focus is its preclinical candidate ALN1003, a non-hormonal oral small molecule for obesity. However, with only $0.354 million in cash as of March 31, 2026, and a stockholders' equity of $2.153 million (violating Nasdaq's $2.5 million minimum requirement), the company faces imminent delisting and going concern risks. While preclinical mouse data for ALN1003 has shown positive weight loss and metabolic improvements, the lack of clinical validation and severe capital constraints make the stock highly speculative and a clear 'Sell' for risk-averse investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company is unable to raise capital or find a strategic partner, leading to Nasdaq delisting, suspension of operations, and eventual board-directed dissolution and liquidation.

Base CaseCentral scenario

The company fails to secure a major strategic transaction or substantial non-dilutive partnership, leading to continued heavy dilution through micro-cap equity offerings or eventual delisting from Nasdaq. Preclinical development of ALN1003 remains stalled or progresses slowly due to capital constraints.

Bull CaseUpside scenario

ALN1003 represents a highly differentiated, oral, non-hormonal, and non-incretin small-molecule approach to treating obesity and metabolic syndrome. Preclinical mouse models demonstrate multi-axis efficacy, including dose-dependent weight loss, preferential reduction of fat mass while preserving lean mass, improved insulin sensitivity (HOMA-IR), and qualitative reductions in hepatic steatosis and NAS scores. If these multi-organ metabolic benefits translate successfully to humans, ALN1003 could capture a significant share of the massive obesity and MASLD markets as a preferred alternative or combination partner to injectable GLP-1 therapies.

Scenarios reflect our research view at the research date.

Key Investment Merits

ALN1003 offers a differentiated, non-hormonal, non-incretin oral mechanism of action for obesity, potentially preserving lean muscle mass unlike GLP-1 receptor agonists.
Preclinical diet-induced obesity (DIO) mouse models demonstrated up to 30.5% body weight reduction and significant improvements in insulin resistance and liver histology.

Key Investment Risks

Severe liquidity constraints with only $0.354 million in cash as of March 31, 2026, creating substantial going concern risk.
Non-compliance with Nasdaq Listing Rule 5550(b)(1) due to stockholders' equity falling below $2.5 million, risking delisting.
ALN1003 is entirely preclinical and has not yet been evaluated in human clinical trials, presenting high scientific and regulatory hurdles.

Thesis Invalidation Triggers

Execution of a highly favorable strategic merger or reverse merger that fully funds the obesity pipeline.
Securing a major licensing deal with upfront non-dilutive cash from a large pharmaceutical partner.
Regaining compliance with Nasdaq listing standards through a successful capital raise.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.